Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Monday, 07 / 23 / 2018

Articles

Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

GUIDELINE

Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)

Jinlin Hou*,1, Guiqiang Wang2, Fusheng Wang3, Jun Cheng4, Hong Ren5, Hui Zhuang6, Jian Sun1, Lanjuan Li7, Jie Li6, Qinghua Meng8, Jingmin Zhao9, Zhongping Duan10, Jidong Jia11, Hong Tang12, Jifang Sheng7, Jie Peng1, Fengmin Lu6, Qing Xie13, Lai Wei*,14, Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association

1Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
2Department of Infectious Diseases, Center for Liver Diseases, Peking University First Hospital, Beijing, China
3The Institute of Translational Hepatology, 302 Hospital of PLA, Peking University, Beijing, China
4Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China
5Institute for Viral Hepatitis, the Key Laboratory of Molecular Biology for Infectious Diseases, the second Affiliated Hospital of Chongqing Medical University, Chongqing, China
6Department of Microbiology of Peking University Health Science Center, Beijing, China
7State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
8Serious Illness Medicine Inpatient Area, Beijing Youan Hospital, Capital Medical University, Beijing, China
9Department of Pathology, 302 Hospital of PLA, Peking University, Beijing, China
10Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China
11Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
12Center of Infectious Diseases, West China Hospital of Sichuan University, Division of Infectious Diseases, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China
13Department of Infectious Diseases, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai, China
14Hepatology Institute, Peking University People’s Hospital, Beijing, China

*Correspondence to: Jinlin Hou, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, No. 1838 North Guangzhou avenue, Guangzhou 510515, China. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; Lai Wei, Peking University People’s Hospital, Peking University Hepatology Institute, No. 11 Xizhimen South Street, Beijing 100044, China. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2017;5(4):297-318 DOI: 10.14218/JCTH.2016.00019

Received: May 3, 2016 Accepted: January 16, 2017 Published online: November 12, 2017

This guideline is established to standardize the prevention, diagnosis and antiviral therapy of chronic hepatitis B (CHB). For other treatment regimens and methods involving CHB, please refer to relevant guidelines and consensuses.

The Chinese Society of Hepatology, Chinese Medical Association (CMA) and the Society of Infectious Diseases, CMA organized relevant native experts to establish this Guideline of Prevention and Treatment for Chronic Hepatitis B (1st version) in 2005, and made the first revision in 2010. In the past 5 years, great progress has been made in the native and foreign fundamental and clinical research with respect to CHB, necessitating additional revision of this guideline.

This guideline is intended to help clinicians make reasonable decisions in the diagnosis, prevention and antiviral therapy of CHB. However, it is not a compulsory standard and does not include or solve all problems in CHB diagnosis, treatment and management. Therefore, clinicians must develop comprehensive and reasonable diagnosis as well as treatment plan for individual patients according to his/her own professional knowledge, clinical experience and available medical resources, based on a full understanding of best clinical evidence relating to this disease and careful consideration of the patient’s specific condition and intention. We will continue to update and improve this guideline according to relevant native and foreign developments.

 

Journal of Clinical and Translational Hepatology 2017 vol. 5 297-318 Html ] [ PDF Full-text ]

© The Authors 2017. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 

 logo

You are here: Home